This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klein, H. H. Articles by Kreuzer, H. Search for Related Content PubMed PubMed Citation Articles by Klein, H. H. Articles by Kreuzer, H.

Circulation, Vol 69, 1000-1005, Copyright © 1984 by American Heart Association

ARTICLES

The effect of two different diltiazem treatments on infarct size in ischemic, reperfused porcine hearts

HH Klein, M Schubothe, K Nebendahl and H Kreuzer

The effect of diltiazem on the development of infarcts was investigated in porcine hearts. The left anterior descending coronary artery was occluded in each of 32 anesthetized pigs for 75 min and was reperfused for 4 hr. Diltiazem (15 micrograms/kg X min) was infused in 11 pigs for 30 min before occlusion (therapy A) and in another eight pigs before reperfusion (therapy B). Eleven pigs served as controls. Tissue concentrations of adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD) were determined in transmural needle biopsy samples taken from the ischemic apex after 70 min of ischemia. The infarct size, expressed as the ratio of the infarcted tissue over the area at risk of necrosis multiplied by 100, amounted to 79 +/- 20% in the control group. Although there was no significant difference between hemodynamics in the control and the treated groups, pretreatment with diltiazem significantly reduced infarct size (53 +/- 26%; p = .025). Reduction of infarct size by therapy B did not reach the required level of significance (66 +/- 33%). The ischemic loss of ATP and NAD was significantly lower in the pretreated group, which further indicates that the beneficial effect of diltiazem was exerted primarily during ischemia and not during reperfusion.

This article has been cited by other articles:

				Q.-D. Wang, J. Pernow, P.-O. Sjoquist, and L. Ryden Pharmacological possibilities for protection against myocardial reperfusion injury Cardiovasc Res, July 1, 2002; 55(1): 25 - 37. [Abstract] [Full Text] [PDF]

				T. Matsusaka, N. Hasebe, Y.-T. Jin, J. Kawabe, and K. Kikuchi Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits Cardiovasc Res, June 1, 2002; 54(3): 568 - 575. [Abstract] [Full Text] [PDF]

				A. Kroner, R. Seitelberger, J. Schirnhofer, O. Bernecker, R. Mallinger, S. Hallstrom, M. Ploner, and B.K. Podesser Diltiazem during reperfusion preserves high energy phosphates by protection of mitochondrial integrity Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 224 - 231. [Abstract] [Full Text] [PDF]

				A. Gourine, A. Gonon, P.-O. Sjoquist, and J. Pernow Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium Cardiovasc Res, July 1, 2001; 51(1): 100 - 107. [Abstract] [Full Text] [PDF]

				R. Schulz, H. Post, A. Jalowy, U. Backenkohler, H. Dorge, C. Vahlhaus, and G. Heusch Unique Cardioprotective Action of the New Calcium Antagonist Mibefradil Circulation, January 19, 1999; 99(2): 305 - 311. [Abstract] [Full Text] [PDF]

				P. Theroux, J. Gregoire, C. Chin, G. Pelletier, P. de Guise, and M. Juneau Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial J. Am. Coll. Cardiol., September 1, 1998; 32(3): 620 - 628. [Abstract] [Full Text] [PDF]

				A. E. Skolnick and W. H. Frishman Calcium Channel Blockers in Myocardial Infarction Arch Intern Med, July 1, 1989; 149(7): 1669 - 1677. [Abstract] [PDF]